Syensqo and Emulseo announce strategic partnership for advanced applications in the healthcare sector

Exploring new opportunities within the fast-growing market of microfluidics

BORDEAUX, France, Feb. 20, 2025 /PRNewswire/ — Syensqo, a leading specialty chemicals company, is pleased to announce a strategic partnership with Emulseo, a French company specialized in formulations for microfluidic technology – the manipulation of liquids at microscopic scale.

Under this agreement, Emulseo will include Syensqo’s advanced solution, Galden® PFPE in its Fluo-Oil range of products to provide its customers with an essential component in creating reliable and performant droplet-based microfluidic analyses.

Droplet-based microfluidics analysis is a widely used technique for the study and manipulation of liquids at a micro-scale using liquid micro-droplets. It has diverse applications, particularly in healthcare as it is one of the most precise and efficient ways to study DNA strands, cells, chemicals, or drugs using very small amounts of material. For example, it is used for the diagnosis of cancer diseases from blood samples, for the development of antibiotics and therapeutics treatments, and for conducting rapid COVID-19 testing through digital PCR.

The partnership with Emulseo will leverage Syensqo’s Galden® PFPE, a family of inert, high-performance, fluorinated fluids with outstanding properties enabling optimal performances of microfluidic systems thanks mainly to their chemical inertness, low viscosity and optical transparency.

“We are thrilled to partner with Emulseo and bring our Galden® PFPE to the forefront of microfluidics technology,” said Peter Browning, President of the Specialty Polymers Global business unit at Syensqo. “This collaboration underscores our commitment to innovation and expanding the applications of our materials to advance humanity, as our PFPE, usually used in the electronics industry, will now contribute to save lives through cancer detection and faster vaccine developments for example.”

“As a young innovative company, Emulseo is extremely proud to partner with a European industry leader such as Syensqo with a clear ambition to support innovation and to contribute to the development of cutting edge technologies in the health sector” added Emulseo CEO, Florine Maes. “Syensqo’s high performance chemicals combined with our expertise and tailor-made quality controls for microfluidic requirements, will enhance our product offerings to meet our commitments to our scientific and industrial customers worldwide.”

Logo – https://healthtechnologynet.com/wp-content/uploads/2025/02/Emulseo_Syensqo_Logo.jpg

Contact: sales@emulseo.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/syensqo-and-emulseo-announce-strategic-partnership-for-advanced-applications-in-the-healthcare-sector-302377201.html

SOURCE Emulseo

Staff

Recent Posts

CannaPharmaRX Provides Corporate Update and Outlines Growth Strategy for 2026

CALGARY, AB / ACCESS Newswire / January 12, 2026 / CannaPharmaRX, Inc. (OTC PINK:CPMD), an…

4 hours ago

TempraMed Closes C$2.5 Million Fully Subscribed Private Placement

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…

7 hours ago

TruuCONNECT NJ Statewide Digital Hub Empowers Users to Find Verified, Local Community Resources and Support – Anonymously and in Real Time

MOUNT LAUREL, N.J., Jan. 12, 2026 /PRNewswire/ -- Born out of a partnership between the…

7 hours ago

Nuvo Unveils Large-Scale AI-Ready Pregnancy Dataset Built on Real-World Maternal and Fetal Physiology

Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into…

7 hours ago

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer’s Disease Research

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision…

7 hours ago

RxAnte Announces Strategic Growth Investment from Primus Capital

PORTLAND, Maine, Jan. 12, 2026 /PRNewswire/ -- RxAnte, the leading provider of analytics, software, and…

7 hours ago